Skip to main content
OpenTrials
Completed

NCT Number: NCT01745250

Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile

The purpose of this study is to demonstrate the efficacy and safety of Emervel Lips and Juvederm Ultra smile

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Medical Skin center

Düsseldorf, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female subjects aged 18 to 65 years.
  • Subjects with the intention to undergo lip augmentation treatment.
  • Subjects treatment-naïve for lip augmentation treatment
  • Subjects with lip appearance judged by the treating investigator to be suitable for lip line treatment
  • Subjects with signed informed consent.

Exclusion criteria

  • Concomitant anticoagulant therapy and therapy with inhibitors of platelet aggregation (e.g. aspirin or other nonsteroidal anti-inflammatory drugs [NSAIDs]), Omega-3 or vitamin E within 10 days before study treatment, or a history of bleeding disorders.
  • Prior surgery or tattoo to the upper or lower lip or lip line.
  • Presence of any abnormal lip structure, such as a scar or lump or severe lip asymmetry.
  • Previous tissue augmenting therapy in the lip area (including oral commissures, marionette and perioral lines) with HA or collagen filler, or laser treatment, within 12 months before study entry.
  • Permanent implant or treatment with non-HA or non-collagen filler in the area surrounding the lips (including nasolabial folds, oral commissures, marionette and perioral lines).
  • History of herpes labialis with an outbreak within 4 weeks of study entry or with 4 or more outbreaks in the 12 months before study entry.
  • Active skin disease, inflammation or related conditions, such as infection, psoriasis and herpes zoster near or on the area to be treated.
  • History of angioedema.
  • Previous hypersensitivity to HA.
  • Previous hypersensitivity to lidocaine or other amide-type anaesthetics
  • Cancerous or precancerous lesions in the area to be treated.
  • Immunosuppressive therapy, chemotherapy, treatment with biologics or systemic corticosteroids within 3 months before study treatment.
  • Pregnancy or breast feeding.
  • Participation in any other clinical study within 30 days before inclusion.
  • Other condition preventing the subject to entering the study in the investigator's opinion, e.g. subjects not likely to avoid other facial cosmetic treatments below the level of the lower orbital rim, subjects anticipated to be unreliable or incapable of understanding the study assessment or unrealistic expectations of treatment result.
  • Study staff or close relative to study staff (e.g. parents, children, siblings or spouse).

Treatment and study plan

Emervel Lips

Device

Lip treatment of both upper and lower lip

Juvederm Ultra Smile

Device

Lip treatment of both upper and lower lip

Primary outcomes

  1. Local tolerability

    Time frame: 14 days

    To assess local tolerability after treatment including erythema, bruising, itching, swelling, pain/ tenderness at 14 days. Number of subjects reporting the events will be analysed.

Secondary outcomes

  1. AE reporting

    Time frame: 24 weeks

    To evaluate long-term safety throughout the study period

  2. Global Aesthetic Improvement Scale (GAIS)

    Time frame: Week 2 to week 24

    To evaluate esthetic change of lips from baseline using GEIS

  3. Lip Fullness Grading Scale (LFGS)

    Time frame: 0-24 weeks

    To evaluate esthetic change of lips from baseline using LFGS

  4. Subject's satisfaction

    Time frame: 0-24 weeks

    To evaluate subjects satisfaction in terms of a subject satisfaction questionnaire

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Official study title

A Randomised, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Dec 10, 2012
Registry last updated
Aug 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.